OTCMKTS:MEOBF - Mesoblast Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.90 -0.10 (-10.00 %)
(As of 03/22/2019 04:00 PM ET)
Previous Close$0.90
Today's Range$0.90 - $0.90
52-Week Range$0.70 - $1.75
Volume600 shs
Average Volume460 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; and JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in epidermolysis bullosa. The company was founded in 2004 and is headquartered in Melbourne, Australia.

Receive MEOBF News and Ratings via Email

Sign-up to receive the latest news and ratings for MEOBF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:MEOBF
CUSIPN/A
CIKN/A
Phone61 3 9639 6036

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Mesoblast (OTCMKTS:MEOBF) Frequently Asked Questions

What is Mesoblast's stock symbol?

Mesoblast trades on the OTCMKTS under the ticker symbol "MEOBF."

Has Mesoblast been receiving favorable news coverage?

Media coverage about MEOBF stock has been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Mesoblast earned a news sentiment score of 0.9 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an effect on the company's share price in the next few days.

Who are some of Mesoblast's key competitors?

What other stocks do shareholders of Mesoblast own?

Who are Mesoblast's key executives?

Mesoblast's management team includes the folowing people:
  • Dr. Silviu Itescu, Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director (Age 62)
  • Dr. Donna L. Skerrett, Chief Medical Officer (Age 62)
  • Mr. Roger D. Brown BA, Head of Spinal Orthopedic Disorders
  • Mr. Michael Schuster MS, BSc, MBA, Head of Pharma Partnering (Age 42)
  • Dr. Kenneth M. Borow M.D., Exec. (Age 71)

How do I buy shares of Mesoblast?

Shares of MEOBF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mesoblast's stock price today?

One share of MEOBF stock can currently be purchased for approximately $0.90.

What is Mesoblast's official website?

The official website for Mesoblast is http://www.mesoblast.com.

How can I contact Mesoblast?

The company can be reached via phone at 61 3 9639 6036.


MarketBeat Community Rating for Mesoblast (OTCMKTS MEOBF)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  44 (Vote Outperform)
Underperform Votes:  34 (Vote Underperform)
Total Votes:  78
MarketBeat's community ratings are surveys of what our community members think about Mesoblast and other stocks. Vote "Outperform" if you believe MEOBF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MEOBF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel